Posted by Michael Wonder on 18 Sep 2024
Making more new cancer treatments available for New Zealanders
18 September 2024 - PHARMAC is consulting on a proposal to fund the medicine lenvatinib mesylate for three types of cancer and has also issued a request for tender to secure the supply of another cancer medicine, bevacizumab.
Lenvatinib mesylate can treat kidney, thyroid, and liver cancer and, if approved, would be funded from 1 December 2024.
